Due to shared expression on the surface of tumor cells and healthy tissue, the risk of on-target-off-tumor reactions is significantly increased in the context auf EpCAM-directed CAR T-cell and anti-PD-1 treatment [67]. Here, EPCAM is linked to neoplasm.